文献速递新发突发、热带与寄生虫病

单克隆抗体TB31F在健康无疟疾成人中的安全性、耐受性及减少恶性疟原虫传播活性:一项单中心、开放标签、首次人体、剂量递增、1期试验

Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults.
PubMed 文献 · Lancet Infect Dis · 2022-08-10

该单中心开放标签首次人体剂量递增1期试验在荷兰纳入25名健康无疟疾成人,单次静脉给予0.1、1、3或10 mg/kg TB31F或皮下100 mg,主要结局为不良事件频率与程度。未发生严重或重度不良事件;20名(80%)参与者发生33例1级和6例2级相关不良事件。静脉1、3、10 mg/kg组血清分别维持80%以上传播减少活性至少28、56、84天。

要点

  • 25名健康无疟疾成人接受单次TB31F,未发生严重或重度不良事件。
  • 20名(80%)参与者发生33例1级和6例2级相关不良事件。
  • 静脉1、3、10 mg/kg组分别维持80%以上传播减少活性至少28、56、84天。

核心结论

  • TB31F耐受良好且高效,能够完全阻断恶性疟原虫从人向蚊的传播。
  • 在季节性传播地区,单次给药可能覆盖整个疟疾季节。

研究设计与样本

  • 单中心、开放标签、首次人体、剂量递增、1期临床试验,在荷兰开展。
  • 纳入健康、无疟疾的成人参与者,单次静脉给予0.1、1、3或10 mg/kg TB31F或皮下100 mg TB31F,监测至给药后第84天。
  • 2020年2月17日至12月10日入组25名参与者,每个剂量组n=5。
  • 主要结局为不良事件的频率和程度;通过ELISA检测TB31F血清浓度,用斯氏按蚊和培养的恶性疟原虫配子体进行标准膜喂养试验评估血清传播减少活性。
  • 试验注册号ClinicalTrials.gov NCT04238689。

主要发现

  • 未发生严重或重度不良事件。
  • 所有组中共20名(80%)参与者发生33例1级和6例2级相关不良事件。
  • 静脉给予1 mg/kg、3 mg/kg、10 mg/kg TB31F的参与者血清分别维持80%以上传播减少活性至少28天、至少56天、至少84天。
  • 达到80%传播减少活性的TB31F血清浓度为2.1 μg/mL(95% CI 1.9-2.3)。
  • 根据抗体动力学外推,单次静脉10 mg/kg后80%以上传播减少活性可维持160天(95% CI 136-193)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malaria elimination requires interruption of the highly efficient transmission of Plasmodium parasites by mosquitoes. TB31F is a humanised monoclonal antibody that binds the gamete surface protein Pfs48/45 and inhibits fertilisation, thereby preventing further parasite development in the mosquito midgut and onward transmission. We aimed to evaluate the safety and efficacy of TB31F in malaria-naive participants. METHODS: In this open-label, first-in-human, dose-escalation, phase 1 clinical trial, healthy, malaria-naive, adult participants were administered a single intravenous dose of 0·1, 1, 3, or 10 mg/kg TB31F or a subcutaneous dose of 100 mg TB31F, and monitored until day 84 after administration at a single centre in the Netherlands. The primary outcome was the frequency and magnitude of adverse events. Additionally, TB31F serum concentrations were measured by ELISA. Transmission-reducing activity (TRA) of participant sera was assessed by standard membrane feeding assays with Anopheles stephensi mosquitoes and cultured Plasmodium falciparum gametocytes. The trial is registered with Clinicaltrials.gov, NCT04238689. FINDINGS: Between Feb 17 and Dec 10, 2020, 25 participants were enrolled and sequentially assigned to each dose (n=5 per group). No serious or severe adverse events occurred. In total, 33 grade 1 and six grade 2 related adverse events occurred in 20 (80%) of 25 participants across all groups. Serum of all participants administered 1 mg/kg, 3 mg/kg, or 10 mg/kg TB31F intravenously had more than 80% TRA for 28 days or more, 56 days or more, and 84 days or more, respectively. The TB31F serum concentration reaching 80% TRA was 2·1 μg/mL (95% CI 1·9-2·3). Extrapolating the duration of TRA from antibody kinetics suggests more than 80% TRA is maintained for 160 days (95% CI 136-193) following a single intravenous 10 mg/kg dose. INTERPRETATION: TB31F is a well tolerated and highly potent monoclonal antibody capable of completely blocking transmission of P falciparum parasites from humans to mosquitoes. In areas of seasonal transmission, a single dose might cover an entire malaria season. FUNDING: PATH's Malaria Vaccine Initiative.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. van der Boor SC, Smit MJ, van Beek SW, et al. Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults. Lancet Infect Dis. 2022. PMID: 35963275. doi:10.1016/S1473-3099(22)00428-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。